Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Arthritis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Arthritis Other
    Efficacy and Safety of Golimumab Treatment Maintained at 52 Weeks in Patients With Psoriatic Arthritis: Reported at ACR-ARHP - (DGDispatch)
    FDA Approves Labeling Changes, Boxed Warning for Efalizumab - (DGNews)
    New ACR Guidelines Update Strategies for Treating RA - (DGNews)
    Abatacept Improves Juvenile Idiopathic Arthritis in Randomised Withdrawal Trial, but Study Design Questioned - (DGNews)
    Zoledronic Acid Better for Bone Remodelling Than Risedronate in Glucocorticoid-Induced Osteoporosis: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Arthritis Other
      Diagnosis and New Treatments for Gout
      Current Concepts in Pharmacological Management of Juvenile Idiopathic Arthritis
      Current Strategies for the Diagnosis and Management of Spondyloarthropathies
      Inflammatory Arthritis -The Antisynthetase Syndrome
      Inflammatory Arthritis - Gout

      Webcasts/CME archive

       Recent cases - Arthritis Other
        Chronic Tophaceous Gout Presenting as Acute Arthritis During an Acute Illness: A Case Report
        Mycobacterium Tuberculosis Monoarthritis in a Child
        Popliteal Venous Thrombosis in Juvenile Arthritis with Baker Cysts: Report of 3 Cases
        Acute Onset Polyarthritis in Older People: Is it RS3PE Syndrome?
        Symptomatic Hypercalcemia in a Patient with Chronic Tophaceous Gout: A Case Report

        Cases archive
          




        my personal edition > arthritis other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Infliximab Safe, Highly Effective In Treating Refractory Ankylosing Spondylitis

        A DGReview of :"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study."
        Rheumatology Online

        11/21/2002
        By Andrew A. Skolnick


        The anti-tumour necrosis factor alpha antibody, infliximab, appears to be a safe and highly effective therapy for patients with refractory ankylosing spondylitis.

        Dr. Maxime Breban at the, Hopital Cochin, Universite Rene Descartes, in Paris, France, and colleagues evaluated the safety and efficacy of a loading regimen of infliximab in patients with predominantly axial severe ankylosing spondylitis.

        The study involved 50 patients, 76 percent of whom were men and 87 percent of whom were HLA-B27+. Their mean age was 35 years and they had a median disease duration of 13 years. All had active ankylosing spondylitis despite treatment with a non-steroidal anti-inflammatory drug, but were without peripheral arthritis, uveitis or active inflammatory bowel disease.

        Other disease-modifying anti-rheumatic drugs were discontinued at least three months before inclusion and were not allowed during the study. Patients received three infusions of infliximab (5 mg/kg) at the start of the study and at the second and sixth week. They were monitored clinically and biologically until the 24th week, the investigators noted.

        Forty-eight of the 50 patients completed the treatment. In intention-to-treat analysis, all parameters were significantly improved by the second week and generally reached maximal improvement by the eight week.

        The proportion of responders, defined by a reduction greater than or equal to 20 percent in the global assessment of pain or by the ankylosing spondylitis Assessment Study Group (ASAS 20 percent) criteria, and the proportion of patients reaching partial remission were 98, 94 and 70 percent respectively, the investigators reported.

        Relapse, defined as greater than or equal to 50 percent loss of maximal global assessment of pain improvement, occurred in 73 percent of completers, with a median delay of 14 weeks after the third infusion. No serious adverse event related to the treatment was observed.

        "This study confirms, in a large group of severely affected ankylosing spondylitis patients, the remarkable efficacy of infliximab," the researchers concluded. "Relapse usually occurred after discontinuation of the drug, but almost one-third of completers were still free of relapse four months after the last infusion."
        Rheumatology (Oxford) 2002; 11: 1280-1285. "Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send